Importer Application for Controlled Substances by LTS Therapy Systems, LLC
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The notice announces that LTS Therapy Systems, LLC has applied to import a controlled substance, specifically Dimethyltryptamine, for research and development. It clarifies that the application is under review to ensure it aligns with regulatory requirements, and there is a process for public comments or requests for a hearing.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- LTS Therapy Systems, LLC applies to import Dimethyltryptamine
- Public can comment or request a hearing by May 18, 2026
- Import for research and not for commercial sale
Obligations
What this law requires
Registered bulk manufacturers of controlled substances must submit electronic comments or objections regarding LTS Therapy Systems, LLC's application for a registration to import controlled substances.
LTS Therapy Systems, LLC must submit electronic comments or objections to the issuance of the proposed registration before the deadline.
LTS Therapy Systems, LLC must submit any requests for a hearing on the application to the Drug Enforcement Administration before the deadline.
Interested parties may request a hearing on the application submitted by LTS Therapy Systems, LLC for the importation of Dimethyltryptamine.
LTS Therapy Systems, LLC must ensure its business activity concerning Dimethyltryptamine is consistent with what is authorized under 21 U.S.C. 952(a)(2).